En E Kimura

List of Publications by Year
in descending order

73 papers	2,445 citations	257450 24 h-index	214800 47 g-index
76 all docs	76 docs citations	76 times ranked	3515 citing authors

#	Article	IF	Citations
1	The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations. Human Mutation, 2015, 36, 395-402.	2.5	507
2	Efficient and Reproducible Myogenic Differentiation from Human iPS Cells: Prospects for Modeling Miyoshi Myopathy In Vitro. PLoS ONE, 2013, 8, e61540.	2.5	188
3	Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database. Journal of Neuromuscular Diseases, 2017, 4, 293-306.	2.6	125
4	Comparison of the Added Value of Contrast-Enhanced 3D Fluid-Attenuated Inversion Recovery and Magnetization-Prepared Rapid Acquisition of Gradient Echo Sequences in Relation to Conventional Postcontrast T1-Weighted Images for the Evaluation of Leptomeningeal Diseases at 3T. American Journal of Neuroradiology, 2010, 31, 868-873.	2.4	116
5	The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. Human Mutation, 2013, 34, 1449-1457.	2.5	94
6	Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Therapy, 2005, 12, 1099-1108.	4.5	83
7	Female dystrophinopathy: Review of current literature. Neuromuscular Disorders, 2018, 28, 572-581.	0.6	80
8	Mdx respiratory impairment following fibrosis of the diaphragm. Neuromuscular Disorders, 2008, 18, 342-348.	0.6	63
9	Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Human Molecular Genetics, 2008, 17, 2507-2517.	2.9	60
10	Dystrophin Delivery to Muscles of mdx Mice Using Lentiviral Vectors Leads to Myogenic Progenitor Targeting and Stable Gene Expression. Molecular Therapy, 2010, 18, 206-213.	8.2	60
11	Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Orphanet Journal of Rare Diseases, 2013, 8, 60.	2.7	56
12	A highly functional mini-dystrophin / GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Human Molecular Genetics, 2006, 15, 1610-1622.	2.9	52
13	Full-length dystrophin cDNA transfer into skeletal muscle of adultmdx mice by electroporation. Muscle and Nerve, 2003, 27, 237-241.	2.2	46
14	Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. Journal of Neuroinflammation, 2011, 8, 116.	7.2	45
15	Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. Neuromuscular Disorders, 2017, 27, 107-114.	0.6	44
16	Comprehensive analysis for genetic diagnosis of Dystrophinopathies in Japan. Orphanet Journal of Rare Diseases, 2017, 12, 149.	2.7	43
17	DJâ€1 forms complexes with mutant SOD1 and ameliorates its toxicity. Journal of Neurochemistry, 2010, 113, 860-870.	3.9	37
18	Nationwide patient registry for GNE myopathy in Japan. Orphanet Journal of Rare Diseases, 2014, 9, 150.	2.7	37

#	Article	IF	Citations
19	Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of Neurology, 2013, 260, 3023-3029.	3.6	36
20	Derlin-1 overexpression ameliorates mutant SOD1-induced endoplasmic reticulum stress by reducing mutant SOD1 accumulation. Neurochemistry International, 2011, 58, 344-353.	3.8	33
21	Transduction of Full-length Dystrophin to Multiple Skeletal Muscles Improves Motor Performance and Life Span in Utrophin/Dystrophin Double Knockout Mice. Molecular Therapy, 2008, 16, 825-831.	8.2	30
22	Optineurin is potentially associated with TDPâ€43 and involved in the pathogenesis of inclusion body myositis. Neuropathology and Applied Neurobiology, 2013, 39, 406-416.	3.2	30
23	A novel GJB1 frameshift mutation produces a transient CNS symptom of X-linked Charcotâ€“Marieâ€“Tooth disease. Journal of Neurology, 2011, 258, 284-290.	3.6	27
24	Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. American Journal of Pathology, 2016, 186, 1302-1312.	3.8	27
25	Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2018, 13, 93.	2.7	27
26	Efficient repetitive gene delivery to skeletal muscle using recombinant adenovirus vector containing the Coxsackievirus and adenovirus receptor cDNA. Gene Therapy, 2001, 8, 20-27.	4.5	26
27	A reversible lesion of the corpus callosum splenium with adult influenza-associated encephalitis/encephalopathy: a case report. Journal of Medical Case Reports, 2008, 2, 220.	0.8	23
28	Detection and management of cardiomyopathy in female dystrophinopathy carriers. Journal of the Neurological Sciences, 2018, 386, 74-80.	0.6	23
29	Respiratory and cardiac function in japanese patients with dysferlinopathy. Muscle and Nerve, 2016, 53, 394-401.	2.2	22
30	Bcl-2 expression by retrograde transport of adenoviral vectors with Cre-loxP recombination system in motor neurons of mutant SOD1 transgenic mice. Gene Therapy, 2001, 8, 977-986.	4.5	21
31	Significant CMAP decrement by repetitive nerve stimulation is more frequent in median than ulnar nerves of patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2012, 45, 426-428.	2.2	20
32	Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet Journal of Rare Diseases, 2018, 13, 155.	2.7	19
33	Donor origin of multipotent adult progenitor cells in radiation chimeras. Blood, 2005, 106, 3646-3649.	1.4	17
34	Six yearsâ€™ accomplishment of the Initiative on Rare and Undiagnosed Diseases: nationwide project in Japan to discover causes, mechanisms, and cures. Journal of Human Genetics, 2022, 67, 505-513.	2.3	17
35	Myasthenic crisis patients who require intensive care unit management. Muscle and Nerve, 2012, 46, 440-442.	2.2	16
36	National registry of patients with Fukuyama congenital muscular dystrophy in Japan. Neuromuscular Disorders, 2018, 28, 885-893.	0.6	16

#	Article	IF	Citations
37	Treatment of a Japanese Patient with Familial Amyloidotic Polyneuropathy with Orthotopic Liver Transplantation.. Internal Medicine, 1994, 33, 730-732.	0.7	15
38	Usefulness of intraventricular infusion of antifungal drugs through Ommaya reservoirs for cryptococcal meningitis treatment. Journal of the Neurological Sciences, 2015, 358, 259-262.	0.6	15
39	Rescue From Respiratory Dysfunction by Transduction of Full-length Dystrophin to Diaphragm via the Peritoneal Cavity in Utrophin/Dystrophin Double Knockout Mice. Molecular Therapy, 2011, 19, 1230-1235.	8.2	14
40	Muscle Fiber Type-Predominant Promoter Activity in Lentiviral-Mediated Transgenic Mouse. PLoS ONE, 2011, 6, e16908.	2.5	13
41	Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. Journal of the Neurological Sciences, 2010, 297, 101-104.	0.6	12
42	Social involvement issues in patients with Becker muscular dystrophy: A questionnaire survey of subjects from a patient registry. Brain and Development, 2018, 40, 268-277.	1.1	12
43	Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation. Journal of Neuromuscular Diseases, 2018, 5, 193-203.	2.6	12
44	The updated retrospective questionnaire study of sporadic inclusion body myositis in Japan. Orphanet Journal of Rare Diseases, 2019, 14, 155.	2.7	12
45	Abnormal spinal MRI findings in human T-cell lymphotrophic virus type I-associated myelopathy. Clinical Neurology and Neurosurgery, 2009, 111, 624-628.	1.4	11
46	Long-Term Outcome of Polymyositis Treated with High Single-Dose Alternate-Day Prednisolone Therapy. European Neurology, 2012, 68, 117-121.	1.4	11
47	Muscle-dominant wild-type TDP-43 expression induces myopathological changes featuring tubular aggregates and TDP-43-positive inclusions. Experimental Neurology, 2018, 309, 169-180.	4.1	11
48	An adult norovirus-related encephalitis/encephalopathy with mild clinical manifestation. BMJ Case Reports, 2010, 2010, bcr0320102784-bcr0320102784.	0.5	10
49	Effective repetitive dystrophin gene transfer into skeletal muscle of adultmdx mice using a helper-dependent adenovirus vector expressing the coxsackievirus and adenovirus receptor (CAR) and dystrophin. Journal of Gene Medicine, 2005, 7, 1010-1022.	2.8	9
50	Cervical MRI of subacute myelo-optico-neuropathy. Spinal Cord, 2011, 49, 182-185.	1.9	9
51	Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clinical Neurology and Neurosurgery, 2013, 115, 603-606.	1.4	9
52	Multicenter questionnaire survey for sporadic inclusion body myositis in Japan. Orphanet Journal of Rare Diseases, 2016, 11, 146.	2.7	9
53	Muscle pathology of hereditary motor and sensory neuropathy with proximal dominant involvement withTFGmutation. Muscle and Nerve, 2019, 60, 739-744.	2.2	9
54	Heatstroke in patients with Parkinsonâ€™s disease. Neurological Sciences, 2012, 33, 685-687.	1.9	8

#	Article	IF	Citations
55	Tumefactive Multiple Sclerosis. Internal Medicine, 2009, 48, 1113-1114.	0.7	7
56	A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis. Neuromuscular Disorders, 2017, 27, 894-904.	0.6	7
57	Cre/loxP-mediated adenovirus type 5 packaging signal excision demonstrates that core element VI is sufficient for virus packaging. Virology, 2003, 309, 330-338.	2.4	6
58	Regions downstream from the WW domain of dystrophin are important for binding to postsynaptic densities in the brain. Neuromuscular Disorders, 2008, 18, 382-388.	0.6	6
59	The association between dermatomyositis and papillary thyroid cancer: a case report. Rheumatology International, 2012, 32, 959-961.	3.0	6
60	Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs. PLoS ONE, 2018, 13, e0208415.	2.5	6
61	Adenovirus-Mediated Murine Interferon-Î³ Receptor Transfer Enhances the Efficacy of IFN-Î³ in Vivo. Biochemical and Biophysical Research Communications, 2002, 290, 1042-1047.	2.1	5
62	Trends in steroid therapy for Duchenne muscular dystrophy in Japan. Muscle and Nerve, 2016, 54, 673-680.	2.2	5
63	Flexor-dominant myopathic phenotype in patients with His46Arg substitution in the Cu/Zn superoxide dismutase gene. Journal of the Neurological Sciences, 2009, 281, 6-10.	0.6	4
64	Amyotrophic lateral sclerosis in a patient with Kartagener syndrome. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 402-404.	2.1	4
65	Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network. BMC Health Services Research, 2016, 16, 241.	2.2	4
66	Medical Attitudes Survey for Female Dystrophinopathy Carriers in Japan. Internal Medicine, 2018, 57, 2325-2332.	0.7	4
67	Diffusion and ADC-map images detect ongoing demyelination on subcortical white matter in an adult metachromatic leukodystrophy patient with autoimmune Hashimoto thyroiditis. BMJ Case Reports, 2010, 2010, bcr0120102631-bcr0120102631.	0.5	3
68	Fulminant Myelopathy following Neurogenic Proximal Weakness Associated with Human T-Cell Lymphotropic Virus Type I Infection. Internal Medicine, 2011, 50, 919-924.	0.7	3
69	Metabolic complications in myotonic dystrophy type 1: A cross-sectional survey using the National Registry of Japan. Journal of the Neurological Sciences, 2021, 427, 117511.	0.6	3
70	Characteristics of myotonic dystrophy patients in the national registry of Japan. Journal of the Neurological Sciences, 2022, 432, 120080.	0.6	2
71	Chronic inflammatory demyelinating polyneuropathy triggered by interferonâ€Î± for chronic hepatitisÂB virus infection. Neurology and Clinical Neuroscience, 2015, 3, 36-38.	0.4	1
72	Tongue strength in patients with subacute myelo-optico-neuropathy. Journal of Clinical Neuroscience, 2018, 47, 84-88.	1.5	0

#	Article	IF	Citations
73	Patient Registries for International Harmonized Clinical Development. , 2016, , 165-178.		0